INTRODUCTION
============

Non-traumatic subarachnoid hemorrhage (SAH) occupies approximately 5-6% of all strokes.[@B23] The incidence of SAH is around six cases per 100,000 patient years, and the most common cause of SAH is a rupture of a saccular cerebral aneurysm.[@B21] Aneurysmal rebleeding is a serious and disastrous complication of SAH, and it comes with high mortality and morbidity. The incidence of aneurysmal rebleeding is considerably high within hours after the initial SAH (21.5% within 72 hours).[@B8] Unfortunately, re-bleeding cannot be absolutely controlled even in authoritative neurosurgical centers that performs early aneurysm repair, such as aneurysm neck clipping or endovascular coiling. Several investigators have reported that rebleeding occurs more often in patients with advanced age, larger aneurysms, poor clinical condition, and increased systolic arterial blood pressure (SBP) on admission.[@B5][@B12] The incidence of rebleeding was significantly higher in patients with extremely high SBP group (\> 200 mmHg) (55.6%) than in the lower SBP groups (\< 150 mmHg, 150-200 mmHg).[@B7] Therefore, it is important to control the blood pressure.

Nicardipine(Perdipine®) is a dihydropyridine type calcium channel blocker and has strong anti-hypertensive activity and a particular cerebrovascular profile.[@B2] Nicardipine has been used to control blood pressure in severe hypertension after ischemic stroke, traumatic brain injury, intracerebral hemorrhage (ICH), and to improve vasospasm after SAH.[@B9]-[@B11][@B16][@B18]

In a recent study, Qureshi et al.[@B19] reported the feasibility and safety of nicardipine use in treatment of acute hypertension with ICH, and Varelas et al.[@B22] demonstrated nicardipine infusion for controlling elevated blood pressure after SAH. However, the study showing controlling acute hypertension after SAH is limited. The purpose of this study is to evaluate the effectiveness and safety of nicardipine infusion for controlling blood pressure in patients with SAH, and compare the effectiveness for each Fisher grade, for different dose of continuous nicardipine infusion, and for various ranges of systolic blood pressure.

MATERIALS AND METHODS
=====================

We prospectively evaluated 112 patients with ruptured aneurysmal SAH admitted to the intensive care unit and treated them with nicardipine for 29 months period (January 2009-May 2011). The diagnosis of ruptured aneurysmal SAH was made by history, clinical features, either computed tomographic angiography of the brain or four-vessels cerebral angiography to evaluate the presence of an intracranial aneurysm. The content and method was confirmed by association of clinical trial and informed consent was received from patients and/or their family members. Patients with active intracranial bleeding, coagulopathy, pregnancy, myocardial infarction, chronic heart failure, and chronic kidney disease were eliminated from the study along with patients who were infused with other types of calcium channel blocker within two-hour period.

Fifty two patients enrolled, and their age ranged from 22 to 89 with the mean of 56.9. Twenty two patients were male and 30 were female. Nicardipine was diluted with normal saline or 5% dextrose water for intravenous injection, and it was infused until the target blood pressure was reached and settled. The goal of the treatment was to reduce and maintain the SBP less than 140 mmHg and diastolic blood pressure (DBP) less than 100 mmHg (mean arterial pressure less than about 110 mmHg) within 24 hours from the treatment started. Patients were divided into three groups according to the injection period. Pre-injection period refers to the condition before nicardipine injection. Bolus injection period is controlling blood pressure. Continuous injection period is when blood pressure control failed even after the bolus injection of nicardipine. The continuous intravenous nicardipine injection was initiated with a rate of 5 mg/hr. If the mean arterial pressure was not reduced to 110 mmHg after 15 minutes, the infusion dose was increased by 2.5 mg/hr. The 2.5 mg/hr increments continued every 15 minutes until the maximum dose of 15 mg/hr was reached. Blood pressure was monitored using an intra-arterial catheter. We also evaluated the influence of infusion dosage of nicardipine according to SBP/DBP. 1 mg of nicardipine was used in patients with SBP between 140 and 160 mmHg, and 2 mg in patients with SBP between 161 and 180 mmHg.

Data were recorded for all patients using a standard data collection form. The data were analyzed by SPSS (version 12.0). Statical analysis was performed with paired *T*-test and chi-squared test. Statistical significance was established at *p* \< 0.05.

RESULTS
=======

Fifty two patients, who fulfilled the condition, were injected with nicardipine. Their demographics and clinical characteristics are presented in table ([Table 1](#T1){ref-type="table"}).

In forty patients who were not responsive to bolus injection, the mean blood pressure in three periods were compared. From pre-injection period (145.6/80.3 mmHg), 11.4/9.0 mmHg was reduced after bolus injection, whereas 24.7/17.3 mmHg was reduced after continuous injection. The effect of nicardipine in controlling blood pressure was statistically significant (*p* \< 0.001) ([Table 2](#T2){ref-type="table"}).

Effectiveness of nicardipine was analysed according to three conditions : Fisher grade, continuous infusion dose of nicardipine, and ranges of systemic blood pressure. At first, all the subgroups of Fisher grade showed decrease in SBP/DBP using nicardipine. The mean SBP/DBP decreased by 38.0/22.5 mmHg (*p* = 0.037/*p* = 0.038) in Fisher grade I (n = 4), 15.9/7.7 mmHg (*p* = 0.001/*p* = 0.035) in grade II (n = 10), 22.2/15.6mmHg (*p* \< 0.001/*p* = 0.004) in grade III (n = 16), and 28.6/17.2 mmHg (*p* \< 0.001/*p* = 0.001) in grade IV (n = 18), and all of them were statistically significant. However, there was no difference in effectiveness between subgroups. (SBP between subgroups *p* = 0.144, DBP between subgroups *p* = 0.299) ([Table 3](#T3){ref-type="table"}). Secondly, each subgroups with different dosage of nicardipine lowered SBP/DBP. In low dose group (n = 20) (≤5 mg/hr), the mean SBP/DBP decreased by 11.8/7.9 mmHg (*p* \< 0.001/*p* = 0.002). It decreased by 13.1/9.7 mmHg (*p* \< 0.001/*p*= 0.046) in medium dose group (n = 12) (6-10 mg/hr), and 15.0/9.2 mmHg (*p* = 0.003/*p* = 0.007) in high dose group (n = 10) (11-15 mg/hr). There was no difference in effectiveness between subgroups. (SBP between subgroups *p* = 0.575, DBP between subgroups *p* = 0.404) ([Table 4](#T4){ref-type="table"}). Finally, 1 mg of nicardipine was used in patients with SBP between 140 and 160 mmHg (n = 18), and 2 mg in patients with SBP between 161 and 180 mmHg. In patients with SBP below 160 mmHg (n = 9), the mean SBP/DBP decreased by 19.8/14.2 mmHg (*p* \< 0.001/*p* \< 0.001), and it dropped by 48.0/30.8 mmHg (*p* \< 0.001/*p* = 0.008) in patients with SBP above 160 mmHg. There was significant decrease in blood pressure in both groups (SBP in both groups p \< 0.001, DBP in both groups *p* = 0.01) ([Table 5](#T5){ref-type="table"}).

There were few complication during nicardipine infusion ([Table 1](#T1){ref-type="table"}). No patient developed rebleeding and renal dysfunction during the period. In one case, which infused 2.5 mg/hr of nicardipine, the SBP of the patient dropped to 94 mmHg and DBP to 33 mmHg; thus, nicardipine had to be pre-terminated. Cardiogenic problems occurred in four patients. Tachycardia with heart rates more than 120 beats per minute appeared in two patients, and arrhythmia was combined in two patients, in which one of them showed ventricular premature contraction, and another showed atrial fibrillation.

DISCUSSION
==========

Nicardipine, a dihydropyridine calcium channel antagonist, is a vasoselective agent with minimal cardiac inotropic effects.[@B23] This is the ideal agent for short-term management of hypertension because of short half life and relatively rapid onset/offset of action in lowering blood pressure with minimal adverse events.[@B6] Hypotension, arrhythmia and tachycardia were some adverse effects observed in this study but there was no severe events.

There has been studies comparing the effectiveness of nicardipine and sodium nitroprusside or nicardipine and labetalol and evaluating effectiveness of nicardipine in traumatic brain injury, SAH, ICH, arteriovenous malformation, and hypoxic brain injury.[@B13][@B16][@B20] Recently, Varelas et al.[@B22] reported effectiveness and safety of nicardipine infusion in reducing SBP and DBP to pre-specified goal. Nicardipine achieved SBP control in 59.9% of hourly infusion measurements.

Intravenous nicardipine has already been included in the published guidelines for blood pressure control in ischemic stroke, ICH.[@B1][@B4] The recently published guidelines for SAH also include nicardipine, however, without available data for such a use.[@B3]

In this study, continuous injection was the most effective method in decreasing blood pressure compared with bolus injection. In some cases, which we manipulated the injection method from bolus to continuous, the influence of bolus injection cannot be ignored even though nicardipine is a short acting agent. This study also showed no significant difference in effectiveness of nicardipine to control blood pressure for each Fisher grade and for different continuous dosage of nicardipine. Nicardipine showed significant decrease in all the subgroups of each categories; however, there was no significant difference within subgroups of Fisher grade and dosage. On the contrary, the effectiveness of nicardipine was significantly different between a group of SBP with 140-160 mmHg and 161-180 mmHg.

Nicardipine is known as a safe medication. During the research period, there was neither rebleeding nor renal dysfunction. Transient complications, such as hypotension, arrhythmia, and tachycardia, appeared, but patients recovered without any permanent deficit.

The risk of rebleeding decrease as the blood pressure decreases, but lowering the blood pressure is not everything. One study reported a increase in rebleeding risk with blood pressure over 160 mmHg compared with 140 mmHg, and rebleeding incidence decreased when anti-hypertensive treatment was used.[@B17] In contrast, risk of cerebral infarction rate increases with low blood pressure.[@B24] The optimal blood pressure after SAH would dependent on multiple factors. In addition, appropriate management of blood pressure is necessary because most rebleeding occurs due to the change of blood pressure rather than absolute blood pressure level itself.[@B15] The most recent guideline for the management of SAH recommends that \"blood pressure should be monitored and controlled to balance the risk of stroke, hypertension-related rebleeding, and maintenance of cerebral perfusion pressure\" as Class I, Level of Evidence B.[@B3] Until systematic treatment algorithms are developed, the optimal blood pressure may vary considerably and be dependent on physician\'s preferences.

The limitation of this study is that there is no correlation between age, clinical or past medical history and the influence that these factors will have on patient\'s blood pressure. Also medical conditions such as seizure or hydrocephalus were not considered, and the number of study population was too small to represent the accurate outcome. The initial blood pressure of each patient and the reaction to injection were not reflected on setting and reaching a goal blood pressure.

CONCLUSIONS
===========

Nicardipine is an effective medication in controlling acute hypertension or dropping blood pressure in SAH. Because continuous infusion of nicardipine has better effects in blood pressure control, it is recommendable when blood pressure is not controlled with bolus infusion if there is no symptom of adverse effects. There was no significant difference in effectiveness of nicardipine within subgroups of Fisher grade and infusion dosage. It was found that higher dose of nicardipine injection with higher SBP is more effective in controlling blood pressure. Nicardipine also seems to be safe except for very few unsevere complications. A systemic study with larger number of patients will be necessary to plan a more precise guideline for the use of nicardipine in controlling blood pressure with SAH.
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Demographics and clinical characteristics of the patients with subarachnoid hemorrhage treated with intravenous nicardipine.
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Average SBP, DBP in pre-injection period, bolus injection period and continuous injection period.
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SBP = systolic blood pressure; DBP = diastolic blood pressure
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Average of pre and post SBP and DBP for each Fisher grade. (SBP between subgroups *p*= 0.144, DBP between subgroups *p*= 0.299)
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###### 

Average of pre and post SBP and DBP in different dosage of nicardipine. (SBP between subgroups *p*= 0.575, DBP between subgroups *p*= 0.404)
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###### 

Average of pre and post SBP and DBP, in patients with SBP 140-160 mmHg and 161-180 mmHg. Patients with SBP lower than 140 mmHg were excluded. (SBP in both groups *p*\< 0.001, DBP in both groups *p*= 0.01)
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